Evidence map›Paper›PMID 27334136›Full record

ArticleWorld journal of urology2017

Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.

Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, Nicolae Calomfirescu, Betsy Brotherton, Juan Manuel Palacios, Averyan Vasylyev, Michael J Manyak

Open access · hybridAbstract read
In one paragraph

Article in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Claus G RoehrbornDepartment of Urology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, J8 142, Dallas, TX, 75390-9110, USA. Claus.roehrborn@utsouthwestern.edu.
Igor Oyarzabal PerezDepartment of Urology, Mendaro Hospital, Mendaro, Gipuzkoa, Spain.
Erik P M RoosDepartment of Urology, Antonius Hospital Sneek, Sneek, The Netherlands.
Nicolae CalomfirescuUrology Clinic, Uroandromed, Bucharest, Romania.
Betsy BrothertonGlaxoSmithKline, Research Triangle Park, NC, USA.
Juan Manuel PalaciosGlaxoSmithKline, Urology, Classic and Established Products, GlaxoSmithKline, Madrid, Spain.
Averyan VasylyevGlaxoSmithKline Pharmaceuticals, GlaxoSmithKline, Kiev, Ukraine.
Michael J ManyakGlaxoSmithKline, Research Triangle Park, NC, USA.
Clinical Emergency Hospital Bucharest · ROGlaxoSmithKline (Spain) · ESGlaxoSmithKline (United States) · USPAREXEL International (United States) · USSouthwestern Medical CenterSt. Antonius Ziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate (in a post hoc analysis of the 2-year CONDUCT study) the characteristics and clinical outcomes of men with moderately symptomatic benign prostatic hyperplasia (BPH) at risk of progression who benefitted from lifestyle changes alone.

methodsPatients were given lifestyle advice and randomized to a fixed-dose combination (FDC) of dutasteride and tamsulosin or watchful waiting (WW) and followed for 24 months. Patients in the WW group were escalated to tamsulosin if any follow-up International Prostate Symptom Score (IPSS) was equal or greater than the baseline value. Improvements in symptoms (change in IPSS) and quality of life [measured by BPH Impact Index (BII) and question 8 of the IPSS (IPSS-Q8)] were analysed in the FDC group, men who initiated tamsulosin (WW-TAM) and men who received no medical intervention (WW-no treatment) and the impact of baseline variables on IPSS determined.

resultsThe adjusted mean decrease in IPSS, BII and IPSS-Q8 at each post-baseline visit over 24 months appeared greater in the FDC (n = 369) and WW-no treatment groups (n = 144) than in the WW-TAM group (n = 229). IPSS improvements appeared similar in the FDC group and WW-no treatment subgroup, except in patients with the greatest degree of bother at baseline (BII 7-13).

conclusionBII at baseline may be a more relevant indicator than symptom severity as to whether a patient with moderate symptoms should receive medical therapy or not.

Indexed as

Watchful Waiting5-alpha Reductase InhibitorsAdrenergic alpha-1 Receptor AntagonistsAgedDisease ProgressionDrug Therapy, CombinationDutasterideHumansLower Urinary Tract SymptomsMaleProstatic HyperplasiaQuality of LifeRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSulfonamides5-alpha Reductase InhibitorsAdrenergic alpha-1 Receptor AntagonistsDutasterideSulfonamidesTamsulosinBenign prostatic hyperplasiaBPH Impact IndexDutasterideLower urinary tract symptomsTamsulosinWatchful waiting

Identifiers

PMID27334136
PMCPMC5332489
OpenAlexW2471284375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.